The Australian Clinical Labs Ltd (ASX: ACL) share price is in focus today after the company released its FY26 earnings, revealing underlying NPAT growth of 4.3% and a final fully franked dividend of 9.25 cents per share.
Image source: Getty Images
What did Australian Clinical Labs report?
- Total revenue down 0.7% to $735.8 million
- Underlying EBIT up 1.7% to $69.2 million (margin expanded to 9.4%)
- Underlying NPAT up 4.3% to $35.5 million
- Underlying EPS increased 8.5% to 18.3 cents per share
- Final fully franked dividend of 9.25 cents per share (up 0.5 cps on FY25)
- Free cash flow before interest, tax and financing of $64.7 million
What else do investors need to know?
Australian Clinical Labs delivered margin improvements thanks to ongoing cost management, procurement savings, and operating efficiencies. While statutory results were impacted by one-off items, including legal settlements and acquisition-related adjustments, underlying profit demonstrated resilience in a soft market.
Around $47.1 million was returned to shareholders through dividends and share buybacks, reflecting strong cash generation even as revenue fell slightly. The company remains conservatively geared with net debt at $37.4 million and continues to focus on disciplined capital management.
ACL also pressed forward with digital initiatives, improved billing processes, and efficiency programs, with nearly 20% of revenue now coming from non-Medicare sources such as commercial contracts and genetics.
What did Australian Clinical Labs management say?
Chief Executive Officer & Executive Director Melinda McGrath said:
I am proud of the result ACL has delivered this year, particularly given the challenging market conditions facing the pathology sector. Amid subdued GP attendance volumes, Medicare fee changes and persistent inflationary pressure, we maintained a clear focus on our strategy, improving margins year on year to 9.4%.
What's next for Australian Clinical Labs?
For FY27, ACL is guiding to revenue between $745 million and $765 million, and underlying EBIT of $67 million to $73 million. The company aims to offset rising wage costs with ongoing automation, price increases in non-Medicare tests, and further digital transformation.
Management expects modest market growth as GP attendances recover, and will keep pursuing improved operational efficiency, technology initiatives, and selective expansion. ACL is also maintaining its buyback program and investing in opportunities to strengthen future earnings growth.
Australian Clinical Labs share price snapshot
Over the past 12 months, Australian Clinical Labs shares have declined 13%, trailing the All Ordinaries Index (ASX: XAO), which has risen 1% over the same period.
